MCID: TRP002
MIFTS: 50

Tropical Spastic Paraparesis

Categories: Infectious diseases, Neuronal diseases

Aliases & Classifications for Tropical Spastic Paraparesis

MalaCards integrated aliases for Tropical Spastic Paraparesis:

Name: Tropical Spastic Paraparesis 12 74 53 15 17 71
Tropical Spastic Paraplegia 12 32
Paraparesis, Tropical Spastic 43
Paraparesis Tropical Spastic 54
Htlv-Associated Myelopathy 12
Tropical Spastic Paralysis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:321
MeSH 43 D015493
SNOMED-CT 67 45129002
ICD10 32 G04.1
UMLS 71 C0030481

Summaries for Tropical Spastic Paraparesis

NINDS : 53 For several decades the term “tropical spastic paraparesis” (TSP) has been used to describe a chronic and progressive disease of the nervous system that affects adults living in equatorial areas of the world and causes progressive weakness, stiff muscles, muscle spasms, sensory disturbance, and sphincter dysfunction. The cause of TSP was obscure until the mid-1980s, when an important association was established between the human retrovirus — human T-cell lymphotrophic virus type 1 (also known as HTLV-1) — and TSP. TSP is now called HTLV-1 associated myelopathy/ tropical spastic paraparesis or HAM/TSP. The HTLV-1 retrovirus is thought to cause at least 80 percent of the cases of HAM/TSP by impairing the immune system. In addition to neurological symptoms of weakness and muscle stiffness or spasms, in rare cases individuals with HAM/TSP also exhibit uveitis (inflammation of the uveal tract of the eye), arthritis (inflammation of one or more joints), pulmonary lymphocytic alveolitis (inflammation of the lung), polymyositis (an inflammatory muscle disease), keratoconjunctivitis sicca (persistent dryness of the cornea and conjunctiva), and infectious dermatitis (inflammation of the skin). The other serious complication of HTLV-1 infection is the development of adult T-cell leukemia or lymphoma. Nervous system and blood-related complications occur only in a very small proportion of infected individuals, while most remain largely without symptoms throughout their lives. The HTLV-1 virus is transmitted person-to-person via infected cells: breast-feeding by mothers who are seropositive (in other words, have high levels of virus antibodies in their blood), sharing infected needles during intravenous drug use, or having sexual relations with a seropositive partner. Less than 2 percent of HTLV-1 seropositive carriers will become HAM/TSP patients.

MalaCards based summary : Tropical Spastic Paraparesis, also known as tropical spastic paraplegia, is related to spastic paraparesis and adult t-cell leukemia. An important gene associated with Tropical Spastic Paraparesis is CNTN2 (Contactin 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pentoxifylline and Zidovudine have been mentioned in the context of this disorder. Affiliated tissues include t cells, spinal cord and breast, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A viral infectious disease that results in inflammation located in spinal cord, has material basis in Human T-lymphotropic virus 1, which is transmitted by sexual contact, and transmitted by breast feeding. The infection has symptom spastic weakness of both legs, has symptom muscle stiffness, has symptom sensory disturbance, and has symptom spasms.

Wikipedia : 74 Tropical spastic paraparesis (TSP), is a medical condition that causes weakness, muscle spasms, and... more...

Related Diseases for Tropical Spastic Paraparesis

Diseases related to Tropical Spastic Paraparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 456)
# Related Disease Score Top Affiliating Genes
1 spastic paraparesis 32.8 IL2 IL10 IFNL3 IFNG
2 adult t-cell leukemia 31.6 JUN IL2RA IL2 FOXP3 CNTN2
3 t-cell adult acute lymphocytic leukemia 31.3 IL2RA IL2 FOXP3 CNTN2
4 thyroiditis 30.8 IL6 IL2 IL10 FOXP3
5 myelitis 30.8 MMP9 IL6 IL17A IL10
6 herpes zoster 30.7 IL2 IL10 IFNG
7 allergic encephalomyelitis 30.7 CCL5 CCL3
8 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.7 IL17A IL10 IFNG FOXP3
9 nervous system disease 30.6 MMP9 IL6 IFNG CXCR3
10 folliculitis 30.6 IL2RA IFNG CCL5
11 measles 30.6 IL6 IL2RA IL2 IFNG CCL5
12 mumps 30.6 IL6 IL2RA IL2 IL10 IFNG
13 prostatitis 30.6 IL6 IL2 IL10
14 chickenpox 30.6 IL6 IL2 IL10 IFNG
15 subacute sclerosing panencephalitis 30.6 IL6 IL2 IL10 IFNG
16 graft-versus-host disease 30.6 IL6 IL2 IL10 IFNG
17 toxoplasmosis 30.5 IL6 IL10 IFNG CCL3
18 myositis 30.5 IL6 IL2 IL17A IFNG
19 human t-cell leukemia virus type 2 30.4 IFNG CNTN2
20 rubella 30.4 IL6 IL2RA IL2 IL10 IFNG
21 cutaneous t cell lymphoma 30.2 IL2RB IL2RA IL2 IFNG CXCR3
22 peripheral nervous system disease 30.2 IL6 IL2 IL17A IL10 IFNG B2M
23 lyme disease 30.2 MMP9 IL6 IL17A CCL3
24 candidiasis 30.2 IL6 IL2 IL17A IL10 IFNG
25 cytomegalovirus infection 30.2 IL6 CCL5 CCL3 B2M
26 spinal cord disease 30.2 IL6 IL2 IL17A IL10 CNTN2
27 central nervous system disease 30.1 MMP9 IL6 IL17A IFNG CXCR3
28 t-cell leukemia 30.1 JUN IL6 IL2RB IL2RA IL2 ERVW-1
29 mycosis fungoides 30.0 IL2RB IL2RA IL2 IFNG FOXP3 CXCR3
30 acquired immunodeficiency syndrome 29.9 IL6 IL2RB IL2RA IL2 IL10 IFNG
31 dermatitis 29.9 IL6 IL2 IL17A IL10 IFNG FOXP3
32 cystitis 29.9 JUN IL6 IL2 IL17A CXCR3
33 schistosomiasis 29.8 IL2 IL17A IL10 IFNG CCL5 CCL3
34 lichen planus 29.8 IL6 IL2 IL17A IL10 IFNG CXCR3
35 uveitis 29.8 TNFRSF18 IL6 IL2RA IL2 IL17A IL10
36 psoriasis 29.2 IL6 IL2RA IL2 IL17A IL10 IFNG
37 skin disease 29.2 IL6 IL2 IL17A IL10 IFNG FOXP3
38 lung disease 29.1 MMP9 IL6 IL17A IL10 IFNG CXCR3
39 human immunodeficiency virus type 1 29.0 IL6 IL2 IL10 IFNG ERVW-1 CCL5
40 osteoporosis 29.0 MMP9 JUN IL6 IL2RA IL2 IL17A
41 alopecia areata 28.9 KLRK1 IL6 IL2RA IL2 IL17A IL10
42 autoimmune disease 27.8 TNFRSF4 TNFRSF18 MMP9 KLRK1 IL6 IL2RA
43 multiple sclerosis 27.8 MMP9 IL6 IL2RB IL2RA IL2 IL17A
44 systemic lupus erythematosus 27.4 TNFRSF4 MMP9 IL6 IL2RB IL2RA IL2
45 htlv-1 associated myelopathy/tropical spastic paraparesis 13.0
46 myelopathy, htlv-1-associated 12.7
47 retrovirus-associated myelopathy 12.0
48 human t-cell leukemia virus type 1 11.9
49 spasticity 10.7
50 fixed drug eruption 10.5 IL2 IFNG

Graphical network of the top 20 diseases related to Tropical Spastic Paraparesis:



Diseases related to Tropical Spastic Paraparesis

Symptoms & Phenotypes for Tropical Spastic Paraparesis

MGI Mouse Phenotypes related to Tropical Spastic Paraparesis:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 B2M CCL5 CXCR3 FOXP3 IFNG IFNL3
2 immune system MP:0005387 10.27 B2M CCL5 CXCR3 FOXP3 IFNG IFNL3
3 cellular MP:0005384 10.24 B2M CXCR3 FOXP3 IFNG IL10 IL2
4 cardiovascular system MP:0005385 10.21 B2M CXCR3 FOXP3 IFNG IL10 IL2
5 growth/size/body region MP:0005378 10.21 B2M FOXP3 IFNG IL10 IL17A IL2
6 digestive/alimentary MP:0005381 10.18 B2M FOXP3 IFNG IL10 IL17A IL2
7 endocrine/exocrine gland MP:0005379 10.16 B2M FOXP3 IFNG IL10 IL17A IL2
8 integument MP:0010771 10.02 B2M FOXP3 IFNG IL10 IL17A IL2RB
9 mortality/aging MP:0010768 9.97 B2M CXCR3 FOXP3 IFNG IL10 IL17A
10 liver/biliary system MP:0005370 9.91 B2M FOXP3 IFNG IL10 IL2 IL2RB
11 neoplasm MP:0002006 9.5 B2M CXCR3 IFNG IL10 IL2 IL6
12 respiratory system MP:0005388 9.36 CXCR3 FOXP3 IFNG IL10 IL17A IL2

Drugs & Therapeutics for Tropical Spastic Paraparesis

Drugs for Tropical Spastic Paraparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
2
Zidovudine Approved Phase 2, Phase 3 30516-87-1 35370
3
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
4
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
5
Mogamulizumab Approved, Investigational Phase 3 1159266-37-1
6 Platelet Aggregation Inhibitors Phase 3
7 Antioxidants Phase 3
8 Free Radical Scavengers Phase 3
9 Protective Agents Phase 3
10 Vasodilator Agents Phase 3
11 Phosphodiesterase Inhibitors Phase 3
12 Radiation-Protective Agents Phase 3
13 Anti-Infective Agents Phase 2, Phase 3
14 Antiviral Agents Phase 2, Phase 3
15 Anti-Retroviral Agents Phase 2, Phase 3
16 Reverse Transcriptase Inhibitors Phase 2, Phase 3
17 Antimetabolites Phase 2, Phase 3
18 Anti-HIV Agents Phase 2, Phase 3
19 Antirheumatic Agents Phase 2, Phase 3
20 Dermatologic Agents Phase 2, Phase 3
21 Immunologic Factors Phase 2, Phase 3
22 Cyclosporins Phase 2, Phase 3
23 Antifungal Agents Phase 2, Phase 3
24 Immunosuppressive Agents Phase 2, Phase 3
25 Calcineurin Inhibitors Phase 2, Phase 3
26
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
27
Infliximab Approved Phase 2 170277-31-3
28 Adjuvants, Immunologic Phase 2
29 interferons Phase 2
30 Interferon-beta Phase 2
31 Janus Kinase Inhibitors Phase 2
32 Gastrointestinal Agents Phase 2
33 Antibodies, Monoclonal Phase 1
34 Antibodies Phase 1
35 Immunoglobulins Phase 1
36
Valproic acid Approved, Investigational 99-66-1 3121
37 HIV Integrase Inhibitors Early Phase 1
38 Raltegravir Potassium Early Phase 1
39 Integrase Inhibitors Early Phase 1
40 Central Nervous System Depressants
41 Neurotransmitter Agents
42 Tranquilizing Agents
43 GABA Agents
44 Anticonvulsants
45 Psychotropic Drugs
46 Antimanic Agents

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens Completed NCT03226119 Phase 4
2 Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
3 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
4 Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial Completed NCT00272480 Phase 2, Phase 3 Zidovudine/lamivudine;Placebos
5 The HAM Ciclosporin Study : an Observational Trial of Therapy in Early or Progressing HAM/TSP Completed NCT00773292 Phase 2, Phase 3 ciclosporin
6 A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM) Active, not recruiting NCT03191526 Phase 3 KW-0761 0.3 mg/kg IV;Placebo (saline)
7 Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a Completed NCT00001785 Phase 2 Recombinant human interferon beta-1a
8 Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL) Recruiting NCT01712659 Phase 2 Ruxolitinib;ruxolitinib
9 An Open, Non-randomised Pilot Study of Anti-TNF-alpha Therapy in Early or Progressing HAM/TSP Terminated NCT00823641 Phase 2 Infliximab
10 Phase I Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2L-15R-Beta; Subunit (CD122) That Blocks IL-15 Action Completed NCT00076843 Phase 1 Hu MiK-Beta-1
11 Evaluation of the MP Diagnostics HTLV Blot 2.4 Unknown status NCT01467024
12 Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study Completed NCT02655471 Early Phase 1 "Raltegravir" and "Zidovudine"
13 A Study of Familial and Genetic Aspects of Adult T-Cell Leukemia/Lymphoma, Tropical Spastic Paraparesis and Infective Dermatitis in Jamaica Completed NCT00340821
14 Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1 Completed NCT01651819
15 MRI Investigation Of The CNS In HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Completed NCT00034723
16 Combined Clinical, Immunological and Virological Assessment of Patients With Multiple Sclerosis (MS) Completed NCT00001156
17 Evaluation of the MP Diagnostics HTLV Blot 2.4 Completed NCT03146013
18 Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1 Completed NCT01754311
19 Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP) Completed NCT01867320 Early Phase 1 Raltegravir
20 Retrovirus Epidemiology Donor Study I (REDS I) Completed NCT00005278
21 Immuno-Virological Evaluation of Human T Cell Lymphotropic Virus Infection and Associated Neurological Diseases Recruiting NCT00001778
22 Electromiography Study in the Respiratory Muscle Training in Human Lymphotropic Virus Type 1 Recruiting NCT03829709
23 Open Label Study of the Clinical and Laboratory Effects of Valproic Acid In HAM/TSP Terminated NCT00519181 Valproic Acid

Search NIH Clinical Center for Tropical Spastic Paraparesis

Cochrane evidence based reviews: paraparesis, tropical spastic

Genetic Tests for Tropical Spastic Paraparesis

Anatomical Context for Tropical Spastic Paraparesis

MalaCards organs/tissues related to Tropical Spastic Paraparesis:

40
T Cells, Spinal Cord, Breast, Eye, Lung, Brain, Skin

Publications for Tropical Spastic Paraparesis

Articles related to Tropical Spastic Paraparesis:

(show top 50) (show all 1548)
# Title Authors PMID Year
1
Reduced Foxp3 expression with increased cytomegalovirus-specific CTL in HTLV-I-associated myelopathy. 54 61
18639344 2008
2
High production of RANTES and MIP-1alpha in the tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). 54 61
17588676 2007
3
Blockade of IL-2 receptor suppresses HTLV-I and IFN-gamma expression in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. 54 61
17409595 2007
4
Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. 54 61
16879249 2006
5
Foxp3 represses retroviral transcription by targeting both NF-kappaB and CREB pathways. 54 61
16652169 2006
6
Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia. 54 61
16387851 2006
7
Involvement of p38 MAPK signaling pathway in IFN-gamma and HTLV-I expression in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. 54 61
15652420 2005
8
Longer dinucleotide repeat polymorphism in matrix metalloproteinase-9 (MMP-9) gene promoter which correlates with higher HTLV-I Tax mediated transcriptional activity influences the risk of HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). 54 61
15465610 2004
9
TIMPs and MMPs expression in CSF from patients with TSP/HAM. 54 61
12697269 2003
10
Detection of myelin basic protein in cerebrospinal fluid and serum from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. 54 61
12564844 2002
11
Detection of myelin basic protein in cerebrospinal fluid. 54 61
12465458 2002
12
High frequencies of Th1-type CD4(+) T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. 54 61
11964301 2002
13
Up-regulation of interleukin-12 receptor expression in peripheral blood mononuclear cells of patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. 54 61
11959151 2002
14
IRF-4 activities in HTLV-I-induced T cell leukemogenesis. 54 61
11846984 2002
15
IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients. 54 61
11717409 2001
16
How does interleukin 15 contribute to the pathogenesis of HTLV type 1-associated myelopathy/tropical spastic paraparesis? 54 61
11080816 2000
17
[Increased activity of metalloproteinases and their inhibitors in cerebrospinal fluid of patients with tropical spastic paraparesis]. 54 61
11016056 2000
18
Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. 54 61
10491011 1999
19
Increased levels of soluble Fas ligand in CSF of rapidly progressive HTLV-1-associated myelopathy/tropical spastic paraparesis patients. 54 61
10430056 1999
20
HTLV-I-infected T cells evade the antiproliferative action of IFN-beta. 54 61
10329542 1999
21
Gelatinase activity of matrix metalloproteinases in the cerebrospinal fluid of various patient populations. 54 61
10604277 1999
22
Predominant expression of Fas ligand mRNA in CD8+ T lymphocytes in patients with HTLV-1 associated myelopathy. 54 61
9817448 1998
23
Matrix metalloproteinase 9 (gelatinase B) in cerebrospinal fluid of HTLV-1 infected patients with tropical spastic paraparesis. 54 61
9633766 1998
24
Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. 54 61
9482906 1998
25
Costimulation of cytokine gene expression in T cells by the human T leukemia/lymphotropic virus type 1 trans activator Tax. 54 61
8648737 1996
26
Sequence analysis of human T cell lymphotropic virus type I (HTLV-I) Env genes amplified from central nervous system tissues of patients with HTLV-I-associated myelopathy or leukemia. 54 61
8778566 1995
27
Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy. 54 61
8301322 1994
28
Virion-associated trans-regulatory protein of human T-cell leukemia virus type I. 54 61
1540409 1992
29
Failure to demonstrate human T cell lymphotropic virus type I in multiple sclerosis patients. 54 61
2189023 1990
30
Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient. 61
31930455 2020
31
Abnormal vitamin D and lipid profile in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. 61
31713009 2020
32
Interferon-γ Secretion Enzyme-Linked Immunospot Assay Determined Among Human T Cell Lymphotropic Virus Type 1-Infected Subjects: A Potential Laboratory Marker for Early HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Diagnosis. 61
31474114 2020
33
EOS, an Ikaros family zinc finger transcription factor, interacts with the HTLV-1 oncoprotein Tax and is downregulated in peripheral blood mononuclear cells of HTLV-1-infected individuals, irrespective of clinical statuses. 61
31856855 2019
34
Noninvasive Detection of Antibodies to Human T-Cell Lymphotropic Virus Types 1 and 2 by Use of Oral Fluid. 61
31597746 2019
35
HTLV-1-infected asymptomatic carriers compared to HAM/TSP patients over-express the apoptosis- and cytotoxicity-related molecules. 61
31317252 2019
36
HTLV-1 contains a high CG dinucleotide content and is susceptible to the host antiviral protein ZAP. 61
31842935 2019
37
HTLV-1 CTCF-binding site is dispensable for in vitro immortalization and persistent infection in vivo. 61
31864373 2019
38
Nutritional status of human T-lymphotropic virus 1 patients: A retrospective study. 61
31677708 2019
39
HTLV-1 proviral load in infective dermatitis associated with HTLV-1 does not increase after the development of HTLV-1-associated myelopathy/tropical spastic paraparesis and does not decrease after IDH remission. 61
31851683 2019
40
An insight to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) pathogenesis; evidence from high-throughput data integration and meta-analysis. 61
31888669 2019
41
TREX1 531C>T Polymorphism is Associated with High Proviral Load Levels in HTLV-1-Infected Persons. 61
31861565 2019
42
Complete genome sequence of human T-cell lymphotropic type 1 from patients with different clinical profiles, including infective dermatitis. 61
31883457 2019
43
HTLV-1 infection: An emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases. 61
31648512 2019
44
HTLV-1 infection of myeloid cells: from transmission to immune alterations. 61
31870397 2019
45
Hormonal and Psychogenic Risk Factors for Erectile Dysfunction in Men with HTLV-1. 61
31521570 2019
46
Population-based prevalence of human T-lymphotropic virus type 1 in sub-Saharan Africa: a systematic review and meta-analysis. 61
31465629 2019
47
Delimitation of the upstream region of NFKBIA gene associated with HTLV-1-associated myelopathy/tropical spastic paraparesis using candidate Tag-SNPs in Peruvian HTLV-1 infected individuals. 61
31226330 2019
48
Tropical spastic paraparesis in autochthon patient. 61
31784111 2019
49
Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). 61
31783764 2019
50
Essential Role of Human T Cell Leukemia Virus Type 1 orf-I in Lethal Proliferation of CD4+ Cells in Humanized Mice. 61
31315992 2019

Variations for Tropical Spastic Paraparesis

Expression for Tropical Spastic Paraparesis

Search GEO for disease gene expression data for Tropical Spastic Paraparesis.

Pathways for Tropical Spastic Paraparesis

Pathways related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 TNFRSF4 TNFRSF18 MMP9 KLRK1 JUN IL6
2
Show member pathways
13.89 TNFRSF4 TNFRSF18 JUN IL6 IL2RB IL2RA
3
Show member pathways
13.71 TNFRSF4 TNFRSF18 JUN IL6 IL2RB IL2RA
4
Show member pathways
13.62 TNFRSF18 JUN IL6 IL2RB IL2RA IL2
5
Show member pathways
13.47 TNFRSF4 TNFRSF18 IL6 IL2RB IL2RA IL2
6
Show member pathways
13.34 TNFRSF4 TNFRSF18 JUN IL6 IL2RB IL2RA
7
Show member pathways
13.32 TNFRSF4 TNFRSF18 MMP9 IL6 IL2RB IL2RA
8
Show member pathways
13.21 MMP9 JUN IL6 IL2 IL10 IFNG
9
Show member pathways
12.95 IL6 IL2RA IL2 IL17A IL10 IFNG
10 12.93 MMP9 JUN IL6 IL2RB IL2RA IL2
11
Show member pathways
12.91 JUN IL6 IL2RB IL2RA IL2 IFNG
12
Show member pathways
12.81 JUN IL6 IL2RB IL2RA IL2
13
Show member pathways
12.7 JUN IL6 IL2 IL17A IL10 IFNG
14
Show member pathways
12.68 JUN IL2RA IL2 IL10 IFNG
15
Show member pathways
12.65 IL6 IL2 IL17A IL10 IFNG
16
Show member pathways
12.6 JUN IL6 IL2RB IL2RA IL2 IL17A
17 12.45 JUN IL6 IL2RB IL2RA IL2 B2M
18
Show member pathways
12.45 IL6 IL2RB IL2RA IL2 IL10 IFNL3
19
Show member pathways
12.43 MMP9 JUN IL6 IL17A IFNG
20
Show member pathways
12.42 JUN IL2RB IL2RA IL2
21
Show member pathways
12.41 IL6 IL2RB IL2RA IL2 IL10 CXCR3
22 12.41 TNFRSF4 TNFRSF18 IL2RB IL2RA IL2 IL17A
23
Show member pathways
12.37 IL6 IL2 IFNG CCL5
24
Show member pathways
12.36 IL6 IL2RA IL2 IL17A IL10 IFNG
25
Show member pathways
12.26 JUN IL6 IL2 IL10
26
Show member pathways
12.17 JUN IL2RB IL2RA IL2 IFNG
27
Show member pathways
12.16 JUN IL6 IL2 IL17A IL10 IFNG
28 12.09 JUN IL6 IL2 IL10
29 12.09 MMP9 IL6 IL2 IFNG
30 12.07 KLRK1 IL6 IL2RB IL2RA IL2 IL10
31 12.06 MMP9 IL6 IL17A IL10
32 12.05 MMP9 JUN IL6 CCL5
33
Show member pathways
12.03 JUN IL2RB IL2RA IL2 IFNG CCL3
34 12.02 JUN IL6 IFNG CCL3
35 12.01 IL6 IL2RB IL2RA IL2 IL10 IFNG
36 11.99 JUN IL6 IL17A IFNG CCL5 CCL3
37 11.91 JUN IL6 IL2 IFNG
38 11.89 JUN IL6 IFNG CCL3
39
Show member pathways
11.89 JUN IL2RA IL2 IFNG FOXP3
40 11.85 IL6 IL2 IL10 IFNG
41
Show member pathways
11.81 IL2RB IL2RA IL2 FOXP3
42 11.79 JUN IL6 IL10
43 11.77 MMP9 IL6 CCL5 CCL3
44
Show member pathways
11.77 MMP9 JUN IL6 IL2 IFNG
45 11.73 JUN IL2 IFNG
46 11.72 MMP9 JUN IL6
47 11.71 MMP9 IL6 IL2 IL17A IL10 IFNG
48 11.67 JUN IL6 IL2 IFNG
49 11.65 KLRK1 IL6 IL10 IFNG
50 11.64 JUN IL6 IFNG

GO Terms for Tropical Spastic Paraparesis

Cellular components related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10 TNFRSF18 MMP9 IL6 IL2 IL17A IL10
2 cell surface GO:0009986 9.7 TNFRSF4 KLRK1 IL2RB IL2RA CXCR3 CNTN2
3 extracellular space GO:0005615 9.65 MMP9 IL6 IL2 IL17A IL10 IFNL3
4 interleukin-2 receptor complex GO:0005893 9.32 IL2RB IL2RA
5 external side of plasma membrane GO:0009897 9.1 TNFRSF4 KLRK1 IL2RB IL2RA IL17A CXCR3

Biological processes related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.02 TNFRSF18 MMP9 JUN IL6 IL2RB IL2
2 cell-cell signaling GO:0007267 9.92 IL2 IL17A CCL5 CCL3
3 MAPK cascade GO:0000165 9.91 IL2RB IL2RA IL2 CCL5 CCL3
4 inflammatory response GO:0006954 9.87 TNFRSF4 IL6 IL17A IL10 CXCR3 CCL5
5 negative regulation of inflammatory response GO:0050728 9.85 IL2RA IL2 IL10 FOXP3
6 cellular response to interleukin-1 GO:0071347 9.81 IL17A CCL5 CCL3
7 positive regulation of T cell proliferation GO:0042102 9.8 IL6 IL2RA IL2 CCL5
8 chemokine-mediated signaling pathway GO:0070098 9.79 CXCR3 CCL5 CCL3
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.78 JUN IL6 CCL5
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.76 MMP9 JUN IL10
11 negative regulation of T cell proliferation GO:0042130 9.74 IL2RA IL10 FOXP3
12 monocyte chemotaxis GO:0002548 9.73 IL6 CCL5 CCL3
13 positive regulation of JAK-STAT cascade GO:0046427 9.7 IL6 IL10 CCL5
14 immune response GO:0006955 9.7 TNFRSF4 IL6 IL2RA IL2 IL17A IL10
15 positive regulation of regulatory T cell differentiation GO:0045591 9.65 IL2 FOXP3
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 TNFRSF18 IL6 IL2 IFNG CCL5
17 T cell chemotaxis GO:0010818 9.64 CXCR3 CCL3
18 regulation of neuroinflammatory response GO:0150077 9.63 MMP9 IL6
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL10 IFNG
20 positive regulation of immunoglobulin secretion GO:0051024 9.63 TNFRSF4 IL6 IL2
21 negative regulation of T-helper 17 cell differentiation GO:2000320 9.61 IL2 FOXP3
22 negative regulation by host of viral transcription GO:0043922 9.61 JUN CCL5 CCL3
23 positive regulation of receptor binding GO:1900122 9.6 MMP9 B2M
24 positive regulation of natural killer cell chemotaxis GO:2000503 9.59 CCL5 CCL3
25 positive regulation of interleukin-23 production GO:0032747 9.58 IL17A IFNG
26 interleukin-2-mediated signaling pathway GO:0038110 9.58 IL2RB IL2RA IL2
27 regulation of regulatory T cell differentiation GO:0045589 9.55 TNFRSF18 IL2RA IL2 IFNG FOXP3
28 regulation of T cell homeostatic proliferation GO:0046013 9.54 IL2RA IL2
29 negative regulation of lymphocyte proliferation GO:0050672 9.54 IL2RA IL2 FOXP3
30 cytokine-mediated signaling pathway GO:0019221 9.32 MMP9 IL6 IL2RB IL2RA IL2 IL17A

Molecular functions related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.28 TNFRSF4 TNFRSF18 MMP9 KLRK1 JUN IL6
2 identical protein binding GO:0042802 9.95 MMP9 JUN CXCR3 CNTN2 CCL5 CCL3
3 tumor necrosis factor-activated receptor activity GO:0005031 9.46 TNFRSF4 TNFRSF18
4 phospholipase activator activity GO:0016004 9.43 CCL5 CCL3
5 CCR5 chemokine receptor binding GO:0031730 9.37 CCL5 CCL3
6 CCR1 chemokine receptor binding GO:0031726 9.26 CCL5 CCL3
7 cytokine activity GO:0005125 9.23 IL6 IL2 IL17A IL10 IFNL3 IFNG
8 interleukin-2 binding GO:0019976 9.16 IL2RB IL2RA
9 interleukin-2 receptor activity GO:0004911 8.96 IL2RB IL2RA

Sources for Tropical Spastic Paraparesis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....